Enhanced Pharmaceutical Compositions for Treating Viral Infections

The inventive concept relates to improved pharmaceutical compositions comprising sulfur-containing nucleosides and nucleotides for treating viral infections, offering enhanced bioavailability, efficacy, and stability.

The original patent disclosed pharmaceutical compositions comprising sulfur-containing nucleosides and nucleotides for treating viral infections. However, these compositions had limitations in terms of bioavailability, efficacy, and stability. The new inventive concept addresses these limitations by introducing novel conjugate compounds, phosphorus oxide linkages, and lipid or sphingolipid modifications, thereby providing improved therapeutic outcomes.

The inventive concept encompasses pharmaceutical compositions comprising sulfur-containing nucleosides or nucleotides conjugated to phosphorus oxide, which can be a phosphorothioate or phosphoroamidate. These compositions may further comprise a lipid or sphingolipid linked to the nucleotide or nucleoside through an amino group or hydroxyl group. Additionally, the inventive concept includes conjugate compounds or salts thereof, where the conjugate compound comprises a nucleotide or nucleoside containing a sulfur-containing base linked by a phosphorus oxide to a sphingolipid or derivative. The phosphorus oxide can be a polyphosphate or polyphosphonate, providing improved stability and solubility of the composition. The inventive concept also includes methods for treating viral infections using these compositions, as well as systems for delivering nucleoside analogs for the treatment of infectious diseases and cancer.

The new inventive concept introduces novel conjugate compounds, phosphorus oxide linkages, and lipid or sphingolipid modifications that enhance the bioavailability, efficacy, and stability of the pharmaceutical compositions. These features are not obvious from the original patent and provide a significant improvement over the prior art.

Alternative embodiments of the inventive concept may include different types of phosphorus oxide linkages, such as phosphorodithioates or phosphoroselenoates. Additionally, the lipid or sphingolipid component may be varied to include different types of lipids or sphingolipids, such as cholesterol or ceramide. The inventive concept may also be adapted for use in different therapeutic areas, such as cancer treatment or gene therapy.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of viral infection treatment and cancer therapy. The improved pharmaceutical compositions may offer enhanced therapeutic outcomes, reduced side effects, and improved patient compliance, making them attractive to pharmaceutical companies and healthcare providers.